Implications of the kinetics of zidovudine in the pregnant baboon following oral administration

Marianne Garland, Hazel H. Szeto, Salha S. Daniel, Pamela J. Tropper, Michael M. Myers, Raymond I. Stark

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Zidovudine (ZDV) therapy in pregnancy reduces mother-to-child transmission of HIV. The action of ZDV in the fetus is thought to be an important contributor to efficacy. Previous research in primates has demonstrated that continuous infusion of ZDV to the mother leads to sustained plasma concentrations in the fetus; however, it has not been determined what concentrations of ZDV are achieved in the fetus following oral administration. The pharmacokinetics of drug distribution to the fetus following oral administration of a 100-mg dose of ZDV to the mother are reported from 6 chronically catheterized baboons. The first order elimination half-life of ZDV from both the mother and fetus was approximately 1.2 hours. The area under the concentration-time curve for the fetus was 77% (r2 = 0.98; p < .001) that of the mother and the estimated peak drug levels in the fetus were 52% (r2 = 0.83; p < .01) those in the mother. The rapid transfer and short half-life of ZDV leads to a drug concentration-time profile that would not sustain levels in the fetus with dosing every 4 hours. After comparing these findings with existing data from pregnant and nonpregnant humans, it seems likely that current dose recommendations for ZDV in pregnancy would not maintain levels of the active intracellular metabolite of ZDV in all fetuses. This may explain in part the 8% failure rate of ZDV prophylaxis. The correlation between fetal and maternal plasma concentrations of ZDV would allow titration of dose based on maternal drug levels to achieve fetal levels within the therapeutic range.

Original languageEnglish (US)
Pages (from-to)433-440
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume19
Issue number5
StatePublished - Dec 15 1998
Externally publishedYes

Fingerprint

Zidovudine
Papio
Oral Administration
Fetus
Mothers
Pharmaceutical Preparations
Half-Life
Pregnancy
Primates
Pharmacokinetics
HIV

Keywords

  • Baboon, maternal
  • Fetal exchange
  • Fetus
  • HIV
  • Pharmacokinetics
  • Placental transfer
  • Pregnancy
  • Zidovudine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Virology

Cite this

Garland, M., Szeto, H. H., Daniel, S. S., Tropper, P. J., Myers, M. M., & Stark, R. I. (1998). Implications of the kinetics of zidovudine in the pregnant baboon following oral administration. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 19(5), 433-440.

Implications of the kinetics of zidovudine in the pregnant baboon following oral administration. / Garland, Marianne; Szeto, Hazel H.; Daniel, Salha S.; Tropper, Pamela J.; Myers, Michael M.; Stark, Raymond I.

In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 19, No. 5, 15.12.1998, p. 433-440.

Research output: Contribution to journalArticle

Garland, Marianne ; Szeto, Hazel H. ; Daniel, Salha S. ; Tropper, Pamela J. ; Myers, Michael M. ; Stark, Raymond I. / Implications of the kinetics of zidovudine in the pregnant baboon following oral administration. In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1998 ; Vol. 19, No. 5. pp. 433-440.
@article{87a5499525bb42b3a3573b33b153bd9c,
title = "Implications of the kinetics of zidovudine in the pregnant baboon following oral administration",
abstract = "Zidovudine (ZDV) therapy in pregnancy reduces mother-to-child transmission of HIV. The action of ZDV in the fetus is thought to be an important contributor to efficacy. Previous research in primates has demonstrated that continuous infusion of ZDV to the mother leads to sustained plasma concentrations in the fetus; however, it has not been determined what concentrations of ZDV are achieved in the fetus following oral administration. The pharmacokinetics of drug distribution to the fetus following oral administration of a 100-mg dose of ZDV to the mother are reported from 6 chronically catheterized baboons. The first order elimination half-life of ZDV from both the mother and fetus was approximately 1.2 hours. The area under the concentration-time curve for the fetus was 77{\%} (r2 = 0.98; p < .001) that of the mother and the estimated peak drug levels in the fetus were 52{\%} (r2 = 0.83; p < .01) those in the mother. The rapid transfer and short half-life of ZDV leads to a drug concentration-time profile that would not sustain levels in the fetus with dosing every 4 hours. After comparing these findings with existing data from pregnant and nonpregnant humans, it seems likely that current dose recommendations for ZDV in pregnancy would not maintain levels of the active intracellular metabolite of ZDV in all fetuses. This may explain in part the 8{\%} failure rate of ZDV prophylaxis. The correlation between fetal and maternal plasma concentrations of ZDV would allow titration of dose based on maternal drug levels to achieve fetal levels within the therapeutic range.",
keywords = "Baboon, maternal, Fetal exchange, Fetus, HIV, Pharmacokinetics, Placental transfer, Pregnancy, Zidovudine",
author = "Marianne Garland and Szeto, {Hazel H.} and Daniel, {Salha S.} and Tropper, {Pamela J.} and Myers, {Michael M.} and Stark, {Raymond I.}",
year = "1998",
month = "12",
day = "15",
language = "English (US)",
volume = "19",
pages = "433--440",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Implications of the kinetics of zidovudine in the pregnant baboon following oral administration

AU - Garland, Marianne

AU - Szeto, Hazel H.

AU - Daniel, Salha S.

AU - Tropper, Pamela J.

AU - Myers, Michael M.

AU - Stark, Raymond I.

PY - 1998/12/15

Y1 - 1998/12/15

N2 - Zidovudine (ZDV) therapy in pregnancy reduces mother-to-child transmission of HIV. The action of ZDV in the fetus is thought to be an important contributor to efficacy. Previous research in primates has demonstrated that continuous infusion of ZDV to the mother leads to sustained plasma concentrations in the fetus; however, it has not been determined what concentrations of ZDV are achieved in the fetus following oral administration. The pharmacokinetics of drug distribution to the fetus following oral administration of a 100-mg dose of ZDV to the mother are reported from 6 chronically catheterized baboons. The first order elimination half-life of ZDV from both the mother and fetus was approximately 1.2 hours. The area under the concentration-time curve for the fetus was 77% (r2 = 0.98; p < .001) that of the mother and the estimated peak drug levels in the fetus were 52% (r2 = 0.83; p < .01) those in the mother. The rapid transfer and short half-life of ZDV leads to a drug concentration-time profile that would not sustain levels in the fetus with dosing every 4 hours. After comparing these findings with existing data from pregnant and nonpregnant humans, it seems likely that current dose recommendations for ZDV in pregnancy would not maintain levels of the active intracellular metabolite of ZDV in all fetuses. This may explain in part the 8% failure rate of ZDV prophylaxis. The correlation between fetal and maternal plasma concentrations of ZDV would allow titration of dose based on maternal drug levels to achieve fetal levels within the therapeutic range.

AB - Zidovudine (ZDV) therapy in pregnancy reduces mother-to-child transmission of HIV. The action of ZDV in the fetus is thought to be an important contributor to efficacy. Previous research in primates has demonstrated that continuous infusion of ZDV to the mother leads to sustained plasma concentrations in the fetus; however, it has not been determined what concentrations of ZDV are achieved in the fetus following oral administration. The pharmacokinetics of drug distribution to the fetus following oral administration of a 100-mg dose of ZDV to the mother are reported from 6 chronically catheterized baboons. The first order elimination half-life of ZDV from both the mother and fetus was approximately 1.2 hours. The area under the concentration-time curve for the fetus was 77% (r2 = 0.98; p < .001) that of the mother and the estimated peak drug levels in the fetus were 52% (r2 = 0.83; p < .01) those in the mother. The rapid transfer and short half-life of ZDV leads to a drug concentration-time profile that would not sustain levels in the fetus with dosing every 4 hours. After comparing these findings with existing data from pregnant and nonpregnant humans, it seems likely that current dose recommendations for ZDV in pregnancy would not maintain levels of the active intracellular metabolite of ZDV in all fetuses. This may explain in part the 8% failure rate of ZDV prophylaxis. The correlation between fetal and maternal plasma concentrations of ZDV would allow titration of dose based on maternal drug levels to achieve fetal levels within the therapeutic range.

KW - Baboon, maternal

KW - Fetal exchange

KW - Fetus

KW - HIV

KW - Pharmacokinetics

KW - Placental transfer

KW - Pregnancy

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0032535650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032535650&partnerID=8YFLogxK

M3 - Article

C2 - 9859956

AN - SCOPUS:0032535650

VL - 19

SP - 433

EP - 440

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 5

ER -